XXXX : surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study.

@entity1 @entity5 @entity1151 @entity1578 @entity157
@entity157 remains a disease with poor prognosis. Liver resection, although the optimal method of management, is associated with a high incidence of @entity5 recurrence ranging between 50-70%, 12 to 18 months following surgery. This study assesses prospectively the results of liver resection as compared to liver resection combined with pre- and post-operative locoregional chemotherapy-immunotherapy in 40 @entity1 suffering from @entity157 . @entity1 were randomly assigned to two groups. Group A (20 @entity1 ) had liver resection only, while Group B (20 @entity1 ) had liver resection combined with pre- and past-operative targeting locoregional chemotherapy-immunotherapy. Five (5) @entity1 died in total: two from Group A and two from Group B, during the first 30 days following surgery due to reasons related to the procedure (post-operative @entity1578 in three, @entity1151 in one). The remaining @entity1 from Group A died 10 months following liver resection due to @entity5 recurrence. From Group A, 17 @entity1 are alive from 3 to 26 months after surgery. Of the 17 alive @entity1 , 10 are free of disease and 7 show intrahepatic recurrence. Thus, @entity5 intrahepatic recurrence occurred in 8 @entity1 of group A. From Group B, all 18 @entity1 are alive and free of disease from 4 to 27 months after surgery. No @entity1 died because of the disease nor has any @entity1 shown @entity5 recurrence. As a conclusion of the present results, liver resection combined with pre- and post-operative targeting locoregional immunotherapy-chemotherapy appears to offer substantial advantages for @entity1 undergoing surgery because of @entity157 .
